Tuesday, March 1, 2011

TRANSPHORM

TRANSPHORM

Also discussed here: TRANSPHORM: Transport related Air Pollution and Health impacts: Integrated Methodologies for Assessing Particulate Matter (UrbanEmissions, Nov. 26, 2010)

Today’s post highlights a new four year project developed by 14 European countries to “improve the knowledge of transport related airborne particulate matter (PM) and its impact on human health and to develop and implement assessment tools for scales ranging from city to Europe”. Each of the 6 sub-projects drill down into specific specialized topics of the traffic-pollution-health theme with reports expected in 2011.



Key Quotes:

“organized into five scientific and technological subprojects (SP) along with SP6 on Project Management and Dissemination:
  • SP1: Transport and emission sources
  • SP2: Air quality and exposure
  • SP3: Relationships between transport related PM and Health
  • SP4: Integrated assessment methodology and tool
  • SP5: Mitigation and adaptation strategies and measures
  • SP6: Management and dissemination of project outcomes”
“key objectives:
  • (i) To improve our understanding of transport sources of size-resolved and speciated (primary and secondary) particulate matter air pollution including non-exhaust, shipping and aviation;
  • (ii) To determine improved emission factors of ultrafine particle number (PN0.1) and mass fractions of PM1, PM2.5 and PM10 through new and existing data for key transport sources;
  • (iii) To conduct targeted measurement campaigns in Rotterdam, Helsinki and Thessaloniki for source apportionment, exposure assessment and model evaluation;
  • (iv) To quantify pollutant-specific human exposure to airborne particulate matter in urban environments resulting from road, shipping, rail and aviation; (v) To develop, improve and integrate air quality dispersion and exposure modelsfor urban and regional scales including long-range transport;
  • (vi) To develop new concentration-response (CRF) or exposure response functions (ERF) linking long and short-term ambient residential exposure to sizeresolved and speciated PM with key health endpoints;
  • (vii) To develop and implement an integrated assessment tool to investigate and analyse the whole chain of processes for selected cities and Europe;
  • (viii) To incorporate micro-environmental concentrations, time-activity patterns, and estimates of internal dose into the health impact assessment (HIA);
  • (ix) To conduct integrated health assessment of a number of selected European cities;
  • (x) To design and implement mitigation and adaptation strategies for European and international policy refinement and development;
  • (xi) To exploit the results of TRANSPHORM through global dissemination and interactions with European and international stakeholders.”
Enhanced by Zemanta

No comments:

Post a Comment